NovImmune is a Geneva-based drug development company focusing on immune mechanisms in order to clinically impact Immune Related Diseases, Inflammation and Organ transplantation. NovImmune has a portfolio of fully human therapeutic monoclonal antibodies at various stages of development, including NI-0501 in final stage of GMP production at Lonza Biologics. These fully human antibodies are generated by NovImmune in house, using technologies licensed from Medarex or Cambridge Antibody Technology.

Recent News

July 13, 2009
NovImmune successfully completes NI-0801 Phase I clinical study

May 12, 2009
NovImmune completes CHF 62.5 (USD 54.8) million equity financing to move portfolio forward and reacquire product rights to lead antibodies

October 30, 2006
NovImmune raises CHF 58 million in Series B Private Financing


Company Info
Country: Switzerland
Industry:    Biotech
Sector: biotechnology
Status: Unrealized
Vehicle: Genevest

Key persons
 Jack Barbut, CEO; Marie Kosco-Vilbois, CSO; Prof. Bernard Mach, Founder & board member

Company website

Endeavour Vision Team
Sven Lingjaerde
© Endeavour Vision SA 2006-2017 Terms & Conditions